Gluten sensitivity among the patients with Inflammatory Bowel Disease and the possibility of therapeutic effect of gluten free diet

Gluten sensitivity among the patients with Inflammatory Bowel Disease and the possibility of therapeutic effect of gluten free diet - Gluten sensitivity in Inflammatory Bowel Disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000034187

Enrollment

200

Registered

2018-10-01

Start date

2018-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Bowel Disease

Interventions

gluten sensitive patients with Inflammatory Bowel Disease have gluten free diet for two weeks and assess an effectiveness of gluten free diet

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: schizophrenia in the Inflammatory Bowel Disease patient who can understand the purpose of this study and be approved to participate by doctor patient who can provide written informed consent

Exclusion criteria

Exclusion criteria: patinet who can't provide written informed consent patient with severe cardiac or liver insufficiency

Design outcomes

Primary

Measure	Time frame
Assessment of gluten sensitivity is determined by the antibody levels of tissue transglutaminase IgA antibody, the deamidated gliadin peptide IgA antibody, gliadin IgA antibody, gliadin IgG anti body. The effectiveness of gluten free diet is assessed by CDAI, Lichtiger Index, GAD-7, PHQ-9 and PHQ-15 before and two weeks later of taking gluten free diet. Improved patients is assessed at four and eight weeks.	—

Measure

Time frame

Assessment of gluten sensitivity is determined by the antibody levels of tissue transglutaminase IgA antibody, the deamidated gliadin peptide IgA antibody, gliadin IgA antibody, gliadin IgG anti body. The effectiveness of gluten free diet is assessed by CDAI, Lichtiger Index, GAD-7, PHQ-9 and PHQ-15 before and two weeks later of taking gluten free diet. Improved patients is assessed at four and eight weeks.

—

Countries

Japan

Contacts

Public Contactyamada hisashi

hyogo medical college department of psychiatry

hisa0820@hyo-med.ac.jp0798-45-6051

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026